Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2198-2206

  Heulens, Inge ^a   D'Hulst, Charlotte ^a,b   Braat, Sien ^a   Rooms, Liesbeth ^a   Kooy, R Frank ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Fragile X syndrome; GABAergic system; Rational therapy

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; DIAZEPAM; GANAXOLONE;

BRAIN REGION; CATAMENIAL EPILEPSY; CENTRAL NERVOUS SYSTEM; DOWN REGULATION; DRUG DEPENDENCE; DRUG TARGETING; EPILEPSY; FRAGILE X SYNDROME; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; INSOMNIA; MEMORY; MIXED ANXIETY AND DEPRESSION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEDATION; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; FRAGILE X SYNDROME; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, GABA-A;

EID: 78650288462     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.211     Document Type: Short Survey

References (58)

1. Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S.L., and Warren, S.T. (2009) Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am. J. Hum. Genet. 85, 503-514.
2. Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S.T., Oostra, B.A., Caskey, C.T., and Nelson, D.L. (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822. (Pubitemid 121001715)
3. Verkerk, A.J.M.H., Pieretti, M., Sutcliffe, J.S., Fu, Y.-H., Kuhl, D.P.A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M.F., Zhang, F., Eussen, B.E., van Ommen, G.-J.B., Blonden, L.A.J., Riggins, G.J., Chastain, J.L., Kunst, C.B., Galjaard, H., Caskey, C.T., Nelson, D.L., Oostra, B.A., and Warren, S.T. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914. (Pubitemid 121001321)
4. Penagarikano, O., Mulle, J.G., and Warren, S.T. (2007) The pathophysiology of fragile X syndrome. Annu. Rev. Genomics Hum. Genet. 8, 109-129.
5. Bassell, G.J. and Warren, S.T. (2008) Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214.
6. Pfeiffer, B.E. and Huber, K.M. (2009) The state of synapses in fragile X syndrome. Neuroscientist 15, 549-567.
7. D'Hulst, C. and Kooy, R.F. (2007) The GABA(A) receptor: a novel target for treatment of fragile X? Trends Neurosci. 30, 425-431.
8. Bakker, C.E., Verheij, C., Willemsen, R., van der Helm, R., Oerlemans, F., Vermey, M., Bygrave, A., Hoogeveen, A.T., Oostra, B.A., Reyniers, E., De Boulle, K., D'Hooge, R., Cras, P., van Velzen, D., Nagels, G., Martin, J.-J., De Deyn, P.P., Darby, J.K., and Willems, P.J. (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78, 23-33. (Pubitemid 24228297)
9. Morales, J., Hiesinger, P.R., Schroeder, A.J., Kume, K., Verstreken, P., Jackson, F.R., Nelson, D.L., and Hassan, B.A. (2002) Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 34, 961-972. (Pubitemid 34722285)
10. Dockendorff, T.C., Su, H.S., McBride, S.M., Yang, Z., Choi, C.H., Siwicki, K.K., Sehgal, A., and Jongens, T.A. (2002) Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34, 973-984. (Pubitemid 34722286)
11. Bakker, C.E. and Oostra, B.A. (2003) Understanding fragile X syndrome: insights from animal models. Cytogenet. Genome Res. 100, 111-123.
12. Kooy, R.F. (2003) Of mice and the fragile X syndrome. Trends Genet. 19, 148-154.
13. Comery, T.A., Harris, J.B., Willems, P.J., Oostra, B.A., Irwin, S.A., Weiler, I.J., and Greenough, W.T. (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. U. S. A. 94, 5401-5404.
14. Irwin, S.A., Patel, B., Idupulapati, M., Harris, J.B., Crisostomo, R.A., Larsen, B.P., Kooy, F., Willems, P.J., Cras, P., Kozlowski, P.B., Swain, R.A., Weiler, I.J., and Greenough, W.T. (2001) Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 98, 161-167.
15. Hinton, V.J., Brown, W.T., Wisniewski, K., and Rudelli, R.D. (1991) Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 41, 289-294.
16. Li, J., Pelletier, M.R., Perez Velazquez, J.-L., and Carlen, P.L. (2002) Reduced cortical synaptic plasticity and GluR1 expression associated with Fragile X mental retardation protein deficiency. Mol. Cell. Neurosci. 19, 138-151.
17. Huber, K.M., Gallagher, S.M., Warren, S.T., and Bear, M.F. (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U. S. A. 99, 7746-7750.
18. Larson, J., Jessen, R.E., Kim, D., Fine, A.-K.S., and du Hoffmann, J. (2005) Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J. Neurosci. 25, 9460-9469.
19. Zhang, Y.Q. and Broadie, K. (2005) Fathoming fragile X in fruit flies. Trends Genet. 21, 37-45.
20. Hagerman, R.J., Berry-Kravis, E., Kaufmann, W.E., Ono, M.Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., Picker, J., Gane, L., and Tranfaglia, M. (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123, 378-390.
21. Heulens, I. and Kooy, R.F. (2010) Fragile X syndrome: from gene discovery to therapy. Front. Biomed. Sci., in press.
22. Bear, M.F., Huber, K.M., and Warren, S.T. (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377. (Pubitemid 38829251)
23. Dolen, G., Carpenter, R.L., Ocain, T.D., and Bear, M.F. (2010) Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 127, 78-93.
24. Bear, M.F. (2005) Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 4, 393-398.
25. Olsen, R.W. and Sieghart, W. (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 60, 243-260.
26. Sieghart, W. (2006) Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol. 54, 231-263.
27. D'Hulst, C., Atack, J.R., and Kooy, R.F. (2009) The complexity of the GABA(A) receptor shapes unique pharmacological profiles. Drug Discov. Today 14, 866-875.
28. Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A.-S., and McNamara, J.O., Eds. (1997) Neuroscience. Sinauer Associates, Sunderland, MA.
29. Schousboe, A. and Waagepetersen, H.S. (2008) GABA neurotransmission: an overview. In Handbook of Neurochemistry and Molecular Neurobiology. Lajtha, A. and Johnson, D.A., Eds. Springer. pp. 213-226.
30. Paredes, R.G. and Agmo, A. (1992) GABA and behavior: the role of receptor subtypes. Neurosci. Biobehav. Rev. 16, 145-170.
31. Henschel, O., Gipson, K.E., and Bordey, A. (2008) GABAA receptors, anesthetics and anticonvulsants in brain development. CNS Neurol. Disord. Drug Targets 7, 211-224.
32. Gantois, I., Vandesompele, J., Speleman, F., Reyniers, E., D'Hooge, R., Severijnen, L.-A., Willemsen, R., Tassone, F., and Kooy, R.F. (2006) Expression profiling reveals involvement of the GABAA receptor subunit d in the fragile X syndrome. Neurobiol. Dis. 21, 346-357.
33. A receptor in fragile X syndrome. Brain Res. 1121, 238-245.
34. D'Hulst, C., Heulens, I., Brouwer, J.R., Willemsen, R., De Geest, N., Reeve, S.P., De Deyn, P.P., Hassan, B.A., and Kooy, R.F. (2009) Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 1253, 176-183.
35. Olmos-Serrano, J.L., Paluszkiewicz, S.M., Martin, B.S., Kaufmann, W.E., Corbin, J.G., and Huntsman, M.M. (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 30, 9929-9938.
36. A receptor expression in the seizure-prone fragile X mouse. Neurosci. Lett. 377, 141-146.
37. Adusei, D.C., Pacey, L.K., Chen, D., and Hampson, D.R. (2010) Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59, 167-171.
38. Curia, G., Papouin, T., Seguela, P., and Avoli, M. (2009) Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb. Cortex 19, 1515-1520.
39. Cancedda, L., Fiumelli, H., Chen, K., and Poo, M.M. (2007) Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J. Neurosci. 27, 5224-5235. (Pubitemid 46741781)
40. D'Antuono, M., Merlo, D., and Avoli, M. (2003) Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience 119, 9-13. (Pubitemid 36577406)
41. Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M.T., Chiara, V.D., Musella, A., Prosperetti, C., Calabresi, P., Bernardi, G., and Bagni, C. (2008) Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol. Psychiatry 63, 963-973. (Pubitemid 351602272)
42. Dictenberg, J.B., Swanger, S.A., Antar, L.N., Singer, R.H., and Bassell, G.J. (2008) A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 14, 926-939.
43. Selby, L., Zhang, C., and Sun, Q.-Q. (2007) Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci. Lett. 412, 227-232.
44. Mihalek, R.M., Banerjee, P.K., Korpi, E.R., Quinlan, J.J., Firestone, L.L., Mi, Z.-P., Lagenaur, C., Tretter, V., Sieghart, W., Anagnostaras, S.G., Sage, J.R., Fanselow, M.S., Guidotti, A., Spigelman, I., Li, Z., DeLorey, T.M., Olsen, R.W., and Homanics, G.E. (1999) Attenuated sensitivity to neuroactive steroids in g-aminobutyrate type A receptor delta subunit knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96, 12905-12910.
45. Chang, S., Bray, S.M., Li, Z., Zarnescu, D.C., He, C., Jin, P., and Warren, S.T. (2008) Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263
46. Iversen, L. (2004) GABA pharmacology - what prospects for the future? Biochem. Pharmacol. 68, 1537-1540.
47. Reddy, D.S. and Woodward, R. (2004) Ganaxolone: a prospective overview. Drugs Future 29, 227-242.
48. Takahashi, T., Kajikawa, Y., and Tsujimoto, T. (1998) G-protein-coupled modulation of presynaptic calcium currents and transmitter release by a GABAB receptor. J. Neurosci. 18, 3138-3146. (Pubitemid 28186006)
49. Kaupmann, K., Schuler, V., Mosbacher, J., Bischoff, S., Bittiger, H., Heid, J., Froestl, W., Leonhard, S., Pfaff, T., Karschin, A., and Bettler, B. (1998) Human gamma-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels. Proc. Natl. Acad. Sci. U. S. A. 95, 14991-14996.
50. Gassmann, M., Shaban, H., Vigot, R., Sansig, G., Haller, C., Barbieri, S., Humeau, Y., Schuler, V., Muller, M., Kinzel, B., Klebs, K., Schmutz, M., Froestl, W., Heid, J., Kelly, P.H., Gentry, C., Jaton, A.L., Van der Putten, H., Mombereau, C., Lecourtier, L., Mosbacher, J., Cryan, J.F., Fritschy, J.M., Luthi, A., Kaupmann, K., and Bettler, B. (2004) Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J. Neurosci. 24, 6086-6097.
51. Kulik, A., Vida, I., Lujan, R., Haas, C.A., Lopez-Bendito, G., Shigemoto, R., and Frotscher, M. (2003) Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J. Neurosci. 23, 11026-11035.
52. Dolen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., and Bear, M.F. (2007) Correction of fragile X syndrome in mice. Neuron 56, 955-962.
53. Berry-Kravis, E. and Hagerman, R. (2010) Arbaclofen for the Treatment of Children and Adults with Fragile X syndrome: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study (Abstract). 12th International Fragile X Conference, Detroit, MI.
54. Berry-Kravis, E.M., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D.V., and Hagerman, R. (2009) A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46, 266-271.
55. Fatemi, S.H., Reutiman, T.J., Folsom, T.D., and Thuras, P.D. (2009) GABA(A) receptor downregulation in brains of subjects with autism. J. Autism Dev. Disord. 39, 223-230.
56. Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R.C., and Garner, C.C. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411-413.
57. Cornish, K., Turk, J., and Hagerman, R. (2008) The fragile X continuum: new advances and perspectives. J. Intellect. Disabil. Res. 52, 469-482.
58. Bettler, B., Kaupmann, K., Mosbacher, J., and Gassmann, M. (2004) Molecular structure and physiological functions of GABAB receptors. Physiol. Rev. 84, 835-867.